From Wikipedia the free encyclopedia

Available structures
PDBOrtholog search: PDBe RCSB
AliasesCXCR4, CD184, D2S201E, FB22, HM89, HSY3RR, LAP-3, LAP3, LCR1, LESTR, NPY3R, NPYR, NPYRL, NPYY3R, WHIM, WHIMS, C-X-C motif chemokine receptor 4, WHIMS1
External IDsOMIM: 162643 MGI: 109563 HomoloGene: 20739 GeneCards: CXCR4
RefSeq (mRNA)



RefSeq (protein)



Location (UCSC)Chr 2: 136.11 – 136.12 MbChr 1: 128.52 – 128.52 Mb
PubMed search[3][4]
View/Edit HumanView/Edit Mouse

C-X-C chemokine receptor type 4 (CXCR-4) also known as fusin or CD184 (cluster of differentiation 184) is a protein that in humans is encoded by the CXCR4 gene.[5][6] The protein is a CXC chemokine receptor.[7]


CXCR-4 is an alpha-chemokine receptor specific for stromal-derived-factor-1 (SDF-1 also called CXCL12), a molecule endowed with potent chemotactic activity for lymphocytes. CXCR4 is one of several chemokine co-receptors that HIV can use to infect CD4+ T cells. HIV isolates that use CXCR4 are traditionally known as T-cell tropic isolates. Typically, these viruses are found late in infection. It is unclear as to whether the emergence of CXCR4-using HIV is a consequence or a cause of immunodeficiency.[citation needed]

CXCR4 is upregulated during the implantation window in natural and hormone replacement therapy cycles in the endometrium, producing, in presence of a human blastocyst, a surface polarization of the CXCR4 receptors suggesting that this receptor is implicated in the adhesion phase of human implantation.[citation needed]

CXCR4's ligand SDF-1 is known to be important in hematopoietic stem cell homing to the bone marrow and in hematopoietic stem cell quiescence. It has been also shown that CXCR4 signalling regulates the expression of CD20 on B cells. Until recently, SDF-1 and CXCR4 were believed to be a relatively monogamous ligand-receptor pair (other chemokines are promiscuous, tending to use several different chemokine receptors). Recent evidence demonstrates ubiquitin is also a natural ligand of CXCR4.[8] Ubiquitin is a small (76-amino acid) protein highly conserved among eukaryotic cells. It is best known for its intracellular role in targeting ubiquitylated proteins for degradation via the ubiquitin proteasome system. Evidence in numerous animal models suggests ubiquitin is anti-inflammatory immune modulator and endogenous opponent of proinflammatory damage associated molecular pattern molecules.[9] It is speculated this interaction may be through CXCR4 mediated signalling pathways. MIF is an additional ligand of CXCR4[10]

CXCR4 is present in newly generated neurons during embryogenesis and adult life where it plays a role in neuronal guidance. The levels of the receptor decrease as neurons mature. CXCR4 mutant mice have aberrant neuronal distribution. This has been implicated in disorders such as epilepsy.[11]

CXCR4 dimerization is dynamic and increases with concentration.[12]

Clinical significance[edit]

Drugs that block the CXCR4 receptor appear to be capable of "mobilizing" hematopoietic stem cells into the bloodstream as peripheral blood stem cells. Peripheral blood stem cell mobilization is very important in hematopoietic stem cell transplantation (as a recent alternative to transplantation of surgically harvested bone marrow) and is currently performed using drugs such as G-CSF. G-CSF is a growth factor for neutrophils (a common type of white blood cells), and may act by increasing the activity of neutrophil-derived proteases such as neutrophil elastase in the bone marrow leading to proteolytic degradation of SDF-1. Plerixafor (AMD3100) is a drug, approved for routine clinical use,[13] which directly blocks the CXCR4 receptor. It is a very efficient inducer of hematopoietic stem cell mobilization in animal and human studies. In a small human clinical trial to evaluate the safety and efficacy of fucoidan ingestion (brown seaweed extract), 3g daily of 75% w/w oral fucoidan for 12 days increased the proportion of CD34+CXCR4+ from 45 to 90% and the serum SDF-1 levels, which could be useful in CD34+ cells homing/mobilization via SDF-1/CXCR4 axis.[14]

It has been associated with WHIM syndrome.[15] WHIM like mutations in CXCR4 were recently identified in patients with Waldenström's macroglobulinemia, a B-cell malignancy.[16] The presence of CXCR4 WHIM mutations has been associated with clinical resistance to ibrutinib in patients with Waldenström's macroglobulinemia.[17]

While CXCR4's expression is low or absent in many healthy tissues, it was demonstrated to be expressed in over 23 types of cancer, including breast cancer, ovarian cancer, melanoma, and prostate cancer. Expression of this receptor in cancer cells has been linked to metastasis to tissues containing a high concentration of CXCL12, such as lungs, liver and bone marrow.[18][19] However, in breast cancer where SDF1/CXCL12 is also expressed by the cancer cells themselves along with CXCR4, CXCL12 expression is positively correlated with disease free (metastasis free) survival. CXCL12 (over-)expressing cancers might not sense the CXCL12 gradient released from the metastasis target tissues since the receptor, CXCR4, is saturated with the ligand produced in an autocrine manner.[20] Another explanation of this observation is provided by a study that shows the ability of CXCL12 (and CCL2) producing tumors to entrain neutrophils that inhibit seeding of tumor cells in the lung.[21]

Drug response[edit]

Chronic exposure to THC has been shown to increase T lymphocyte CXCR4 expression on both CD4+ and CD8+ T lymphocytes in rhesus macaques.[22] It has been shown that BCR signalling inhibitors also affect CXCR4 pathway and thus CD20 expression.


CXCR4 has been shown to interact with USP14.[23]

See also[edit]


  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000121966Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000045382Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ Moriuchi M, Moriuchi H, Turner W, Fauci AS (November 1997). "Cloning and analysis of The sigma gene the promoter region of CXCR4, a coreceptor for HIV-1 entry". Journal of Immunology. 159 (9): 4322–9. doi:10.4049/jimmunol.159.9.4322. PMID 9379028. S2CID 36552134.
  6. ^ Caruz A, Samsom M, Alonso JM, Alcami J, Baleux F, Virelizier JL, Parmentier M, Arenzana-Seisdedos F (April 1998). "Genomic organization and promoter characterization of human CXCR4 gene". FEBS Letters. 426 (2): 271–8. doi:10.1016/S0014-5793(98)00359-7. PMID 9599023. S2CID 36571818.
  7. ^ "Gene group: C-X-C motif chemokine receptors (CXCR)". HUGO Gene Nomenclature Committee.
  8. ^ Saini V, Marchese A, Majetschak M (May 2010). "CXC chemokine receptor 4 is a cell surface receptor for extracellular ubiquitin". The Journal of Biological Chemistry. 285 (20): 15566–76. doi:10.1074/jbc.M110.103408. PMC 2865327. PMID 20228059.
  9. ^ Majetschak M (February 2011). "Extracellular ubiquitin: immune modulator and endogenous opponent of damage-associated molecular pattern molecules". Journal of Leukocyte Biology. 89 (2): 205–19. doi:10.1189/jlb.0510316. PMID 20689098. S2CID 24072570.
  10. ^ Bernhagen J, Krohn R, Lue H, Gregory JL, Zernecke A, Koenen RR, Dewor M, Georgiev I, Schober A, Leng L, Kooistra T, Fingerle-Rowson G, Ghezzi P, Kleemann R, McColl SR, Bucala R, Hickey MJ, Weber C (May 2007). "MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment". Nature Medicine. 13 (5): 587–96. doi:10.1038/nm1567. PMID 17435771. S2CID 23194228.
  11. ^ Bagri A, Gurney T, He X, Zou YR, Littman DR, Tessier-Lavigne M, Pleasure SJ (September 2002). "The chemokine SDF1 regulates migration of dentate granule cells". Development. 129 (18): 4249–60. doi:10.1242/dev.129.18.4249. PMID 12183377.
  12. ^ Işbilir A, Möller J, Arimont M, Bobkov V, Perpiñá-Viciano C, Hoffmann C, et al. (November 2020). "Advanced fluorescence microscopy reveals disruption of dynamic CXCR4 dimerization by subpocket-specific inverse agonists". Proceedings of the National Academy of Sciences of the United States of America. 117 (46): 29144–29154. Bibcode:2020PNAS..11729144I. doi:10.1073/pnas.2013319117. PMC 7682396. PMID 33148803.
  13. ^ To LB, Levesque JP, Herbert KE (October 2011). "How I treat patients who mobilize hematopoietic stem cells poorly". Blood. 118 (17): 4530–40. doi:10.1182/blood-2011-06-318220. PMID 21832280. S2CID 2543277.
  14. ^ Irhimeh MR, Fitton JH, Lowenthal RM (June 2007). "Fucoidan ingestion increases the expression of CXCR4 on human CD34+ cells". Experimental Hematology. 35 (6): 989–94. doi:10.1016/j.exphem.2007.02.009. PMID 17533053.
  15. ^ Balabanian K, Levoye A, Klemm L, Lagane B, Hermine O, Harriague J, Baleux F, Arenzana-Seisdedos F, Bachelerie F (March 2008). "Leukocyte analysis from WHIM syndrome patients reveals a pivotal role for GRK3 in CXCR4 signaling". The Journal of Clinical Investigation. 118 (3): 1074–84. doi:10.1172/JCI33187. PMC 2242619. PMID 18274673.
  16. ^ Hunter ZR, Xu L, Yang G, Zhou Y, Liu X, Cao Y, Manning RJ, Tripsas C, Patterson CJ, Sheehy P, Treon SP (March 2014). "The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis". Blood. 123 (11): 1637–46. doi:10.1182/blood-2013-09-525808. PMID 24366360.
  17. ^ Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, et al. (2015). "Ibrutinib in previously treated Waldenstrom macroglobulinemia". N. Engl. J. Med. 372 (15): 1430–40. doi:10.1056/NEJMoa1501548. PMID 25853747.
  18. ^ Sun X, Cheng G, Hao M, Zheng J, Zhou X, Zhang J, Taichman RS, Pienta KJ, Wang J (December 2010). "CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression". Cancer and Metastasis Reviews. 29 (4): 709–22. doi:10.1007/s10555-010-9256-x. PMC 3175097. PMID 20839032.
  19. ^ Balkwill F (July 2004). "Cancer and the chemokine network". Nature Reviews. Cancer. 4 (7): 540–50. doi:10.1038/nrc1388. PMID 15229479. S2CID 205467365.
  20. ^ Mirisola V, Zuccarino A, Bachmeier BE, Sormani MP, Falter J, Nerlich A, Pfeffer U (September 2009). "CXCL12/SDF1 expression by breast cancers is an independent prognostic marker of disease-free and overall survival". European Journal of Cancer. 45 (14): 2579–87. doi:10.1016/j.ejca.2009.06.026. PMID 19646861.
  21. ^ Granot Z, Henke E, Comen EA, King TA, Norton L, Benezra R (September 2011). "Tumor entrained neutrophils inhibit seeding in the premetastatic lung". Cancer Cell. 20 (3): 300–14. doi:10.1016/j.ccr.2011.08.012. PMC 3172582. PMID 21907922.
  22. ^ LeCapitaine NJ, Zhang P, Winsauer P, Walker E, Vande Stouwe C, Porretta C, Molina PE (December 2011). "Chronic Δ-9-tetrahydrocannabinol administration increases lymphocyte CXCR4 expression in rhesus macaques". Journal of Neuroimmune Pharmacology. 6 (4): 540–5. doi:10.1007/s11481-011-9277-4. PMC 3181271. PMID 21484257.
  23. ^ Mines MA, Goodwin JS, Limbird LE, Cui FF, Fan GH (February 2009). "Deubiquitination of CXCR4 by USP14 is critical for both CXCL12-induced CXCR4 degradation and chemotaxis but not ERK activation". The Journal of Biological Chemistry. 284 (9): 5742–52. doi:10.1074/jbc.M808507200. PMC 2645827. PMID 19106094.

Further reading[edit]

External links[edit]